关注公众号
收藏产品 产品详情
分子别名（Synonym）
APRIL,TNFSF13,TALL-2,TRDL-1,CD256,TALL2,ZTNF2
表达区间及表达系统（Source）
Biotinylated Human APRIL, Fc,Avitag (APL-H82F5) is expressed from human 293 cells (HEK293). It contains AA Ala 105 - Leu 250 (Accession # O75888-1).
Predicted N-terminus: Pro
Request for sequence蛋白结构（Molecular Characterization）
This protein carries a human IgG1 Fc tag at the N-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 44.6 kDa. The protein migrates as 45-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
偶联（Conjugate）
Biotin
标记（Labeling）
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
内毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
纯度（Purity）
95% as determined by SDS-PAGE.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
质量管理控制体系（QMS）
产品展示
电泳（SDS-PAGE）
Biotinylated Human APRIL, Fc,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
活性（Bioactivity）-ELISA
Immobilized Human BCMA, His Tag (Cat. No. BCA-H522y) at 2 μg/mL (100 μL/well) can bind Biotinylated Human APRIL, Fc,Avitag (Cat. No. APL-H82F5) with a linear range of 1-20 ng/mL (QC tested).
Protocol
Immobilized Human BCMA, His Tag (Cat. No. BCA-H522y) at 2 μg/mL (100 μL/well) can bind pre-mixed increasing concentrations of Anti-BCMA MAb (Mouse IgG1, the antibody was co developed by SCT and ACRObiosystems) and 0.05 μg/mL (100 μL/well) Biotinylated Human APRIL, Fc,Avitag (Cat. No. APL-H82F5) with a half maximal inhibitory concentration (IC50) of 4.624 μg/mL (Routinely tested).
Protocol
Immobilized Human TACI/TNFRSF13B, Fc Tag at 5 μg/mL (100 μL/well) can bind Biotinylated Human APRIL, Fc,Avitag (Cat. No. APL-H82F5) with a linear range of 5-78 ng/mL (Routinely tested).
Protocol
用户评价 发表评论
药物研发进展 
联系我们 
项目合作